Detalhe da pesquisa
1.
Antibodies to Costimulatory Receptor 4-1BB Enhance Anti-tumor Immunity via T Regulatory Cell Depletion and Promotion of CD8 T Cell Effector Function.
Immunity
; 49(5): 958-970.e7, 2018 11 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-30446386
2.
KIR2DS2 Expression Identifies NK Cells With Enhanced Anticancer Activity.
J Immunol
; 209(2): 379-390, 2022 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35768150
3.
Are we reaching the maximum cure rate for Hodgkin lymphoma?
Hematol Oncol
; 41 Suppl 1: 57-61, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-37294968
4.
Comparative analysis of gene expression platforms for cell-of-origin classification of diffuse large B-cell lymphoma shows high concordance.
Br J Haematol
; 192(3): 599-604, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33249557
5.
Personalized medicine for Hodgkin lymphoma: Mitigating toxicity while preserving cure.
Hematol Oncol
; 39 Suppl 1: 39-45, 2021 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-34105815
6.
Epigenetics of Indolent Lymphoma and How It Drives Novel Therapeutic Approaches-Focus on EZH2-Targeted Drugs.
Curr Oncol Rep
; 23(7): 76, 2021 05 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33937922
7.
Optimizing therapy in advanced-stage Hodgkin lymphoma.
Blood
; 131(15): 1679-1688, 2018 04 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-29500173
8.
Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial.
Lancet Oncol
; 20(5): 649-662, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30948276
9.
Current treatment paradigms for advanced stage Hodgkin lymphoma.
Br J Haematol
; 184(1): 60-71, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30408156
10.
Smart salvage treatment for Hodgkin lymphoma.
Blood
; 139(25): 3563-3564, 2022 06 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-35737409
11.
Baseline PET features to predict prognosis in primary mediastinal B cell lymphoma: a comparative analysis of different methods for measuring baseline metabolic tumour volume.
Eur J Nucl Med Mol Imaging
; 46(6): 1334-1344, 2019 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-30806751
12.
Determinants of ovarian function after response-adapted therapy in patients with advanced Hodgkin's lymphoma (RATHL): a secondary analysis of a randomised phase 3 trial.
Lancet Oncol
; 19(10): 1328-1337, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30220622
13.
Prognostic models for primary mediastinal (thymic) B-cell lymphoma derived from 18-FDG PET/CT quantitative parameters in the International Extranodal Lymphoma Study Group (IELSG) 26 study.
Br J Haematol
; 178(4): 588-591, 2017 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28485042
14.
Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma.
Blood
; 126(8): 950-6, 2015 Aug 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-26089397
15.
The PI3K/mTOR inhibitor PF-04691502 induces apoptosis and inhibits microenvironmental signaling in CLL and the Eµ-TCL1 mouse model.
Blood
; 125(26): 4032-41, 2015 Jun 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-25957390
16.
Short duration immunochemotherapy followed by radioimmunotherapy consolidation is effective and well tolerated in relapsed follicular lymphoma: 5-year results from a UK National Cancer Research Institute Lymphoma Group study.
Br J Haematol
; 173(2): 274-82, 2016 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-26849853
17.
Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) in the management of primary mediastinal B-cell lymphoma: a subgroup analysis of the UK NCRI R-CHOP 14 versus 21 trial.
Br J Haematol
; 175(4): 668-672, 2016 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-27477167
18.
The addition of rituximab to fludarabine and cyclophosphamide chemotherapy results in a significant improvement in overall survival in patients with newly diagnosed mantle cell lymphoma: results of a randomized UK National Cancer Research Institute trial.
Haematologica
; 101(2): 235-40, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26611473
19.
Differential impact of CD27 and 4-1BB costimulation on effector and memory CD8 T cell generation following peptide immunization.
J Immunol
; 193(1): 244-51, 2014 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-24860188
20.
Fcγ receptor dependency of agonistic CD40 antibody in lymphoma therapy can be overcome through antibody multimerization.
J Immunol
; 193(4): 1828-35, 2014 Aug 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-25024386